RBL2

Across TCGA pan-cancer cohorts, RBL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBL2 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RBL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RBL2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, UCEC, and PDAC are the cancer types where RBL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.903	0.754	.010	12	view →
UCEC	OS	Quartile	II,III,IV	0.520	1.000	.022	6	view →
PDAC	DFS	Tertile	III,IV	0.757	0.189	.012	6	view →
LSCC	OS	Median	II,III,IV	0.780	0.903	.036	5	view →
HNSC	DFS	Median	IV	0.666	0.862	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBL2–LUAD (OS)

Open the LUAD breakdown →